{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:20:59Z","timestamp":1792045259766,"version":"4.4.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genomic testing is crucial for the management of ovarian cancer. DNA from biopsies at diagnostic laparoscopies or interval debulking surgery after neoadjuvant chemotherapy, has a high failure rate. At relapse, biopsies may not be feasible. The aim of our study was to evaluate the feasibility and usefulness of measuring genomic instability score (GIS) on cell-free DNA (cfDNA) from ascites.<\/jats:p><jats:p>Patients enrolled in a prospective study (NCT03010124) consented to analysis of biological samples. CfDNA was extracted from 1 to 4 ml of double-centrifuged fresh ascites. Targeted Next-generation sequencing (NGS) including <jats:italic>TP53<\/jats:italic> mutation (<jats:italic>TP53m<\/jats:italic>) was performed on cfDNA to confirm the presence of tumor cfDNA. Single Nucleotide Polymorphism Array estimating somatic copy number alterations (SCNA) was performed to calculate GIS for Homologous-Recombination deficiency (HRD).<\/jats:p><jats:p>Twenty nine ascites were collected from 20 patients with suspected or confirmed OC. 93% (27\/29) samples had detectable cfDNA (median 1120 ng [24-5732]) even when obtained during chemotherapy. A deleterious mutation was identified in 100%, with high allelic frequencies (median 60% [3.3\u201387%]), confirming that cfDNA was tumoral. SCNA analyses on 17 patients showed 11 high GIS, and 6 low GIS. 4 patients with confirmed BRCA mutation had a high GIS on ascites. When available from the same patient, SCNA profiles on ascites and tumor were superimposable.<\/jats:p><jats:p>Ascites is frequent at diagnosis and relapse and yields large amounts of tumoral cfDNA. SCNA analysis on ascitic cfDNA is feasible and can detect the same HRD scar as tumor testing. Ascites could provide an alternative to tumor sampling for HRD and BRCA testing.<\/jats:p>","DOI":"10.1186\/s40364-023-00533-1","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:02:33Z","timestamp":1697760153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients"],"prefix":"10.1186","volume":"11","author":[{"given":"Maria","family":"Kfoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda El","family":"Hazzaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Sanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Blanc","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline Colomba","family":"Blameble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Le Formal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lecerf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Gouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Maulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"issue":"9","key":"533_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc.2016.72","volume":"16","author":"FC Nielsen","year":"2016","unstructured":"Nielsen FC, van Overeem Hansen T, S\u00f8rensen CS. Hereditary breast and Ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016;16(9):599\u2013612.","journal-title":"Nat Rev Cancer"},{"issue":"7353","key":"533_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"issue":"3","key":"533_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and Peritoneal Carcinomas. Clin Cancer Res. 2014;20(3):764\u201375.","journal-title":"Clin Cancer Res"},{"key":"533_CR4","first-page":"49","volume":"60","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and Ovarian cancer. Eur J Cancer Oxf Engl 1990. 2016;60:49\u201358.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"25","key":"533_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"key":"533_CR6","doi-asserted-by":"crossref","unstructured":"Cheng X, Zhang L, Chen Y, Qing C. Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer. J Ovarian Res [Internet]. 2017 Nov 13 [cited 2020 Aug 19];10. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5683341\/.","DOI":"10.1186\/s13048-017-0369-5"},{"key":"533_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","volume":"468","author":"DB Asante","year":"2020","unstructured":"Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in Ovarian cancer using circulating Tumor DNA and cells: ready for prime time? Cancer Lett. 2020;468:59\u201371.","journal-title":"Cancer Lett"},{"issue":"4","key":"533_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DSP, Kaye SB. Meeting the challenge of Ascites in Ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"7353","key":"533_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"key":"533_CR10","doi-asserted-by":"publisher","first-page":"763790","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C. Circulating Tumor DNA and minimal residual Disease (MRD) in solid tumors: current Horizons and Future perspectives. Front Oncol. 2021;11:763790.","journal-title":"Front Oncol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00533-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-023-00533-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00533-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T12:19:51Z","timestamp":1700482791000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-023-00533-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1186\/s40364-023-00533-1","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with good clinical practice and had been authorized by Gustave Roussy Institutional Review Board. All patients included signed an informed consent form (OvBIOMark, NCT03010124).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}